

## Company Profile

EpiAxis Therapeutics is a Canberra based biotechnology company, which is pursuing a discovery and translational program directed at the prevention of metastatic disease. The program is focused on the pivotal enzyme system controlling the proliferation of circulating tumour cells and cancer stem cells. These cells are collectively called Metastasis Initiating Cells (**MIC**) and are believed to be responsible for the initiation and maintenance of metastatic disease. The enzyme target is the nuclear bound lysine-specific demethylase 1 (**LSD1**) & its upstream regulator, the theta isoform of protein kinase C (**PKC<sub>θ</sub>**).

The research identifying this target and the intellectual property (**IP**) that resulted from it was developed by Professor Sudha Rao and colleagues at the University of Canberra (**UC**), Australia. The Company is focused initially on the prevention of metastatic breast cancer, with other MIC mediated diseases such as ovarian, pancreatic, colon, melanoma, lung and liver cancers to be pursued later.

The Company is on track to initiate a Phase 1 program in late 2016, using an “off label” drug that also targets LSD1 in metastatic breast cancer as a “proof of concept” study. Later, one of the Company’s proprietary inhibitors will be nominated as a “druggable candidate” for preclinical development.

EpiAxis is positioning itself to become the leading cancer recurrence prevention company with its proprietary LSD1 & PKC<sub>θ</sub> inhibitors included in the standard of care (**SoC**) for cancer.

The founding CEO of the Company is Dr Jeremy Chrisp.

[www.epiaxistherapeutics.com](http://www.epiaxistherapeutics.com)